Opendata, web and dolomites

GONDOLA SIGNED

Automated Mechanical Peripheral Stimulation for motor rehabilitation in people living with Parkinson’s Disease (PD)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GONDOLA project word cloud

Explore the words cloud of the GONDOLA project. It provides you a very rough idea of what is the project "GONDOLA" about.

balance    recommendations    ideal    disorder    advancing    time    functioning    freezing    risk    nervous    2004    disease    neurostimulations    lessening    patients    neurotransmitter    skills    double    afferent    regard    globally    cure    stimulation    undermine    named    gait    fluidity    basic    symptoms    physical    induce    individuals    spinal    device    quality    10m    mechanical    movements    ourselves    therapies    documented    2040    amps    economic    people    regulate    person    confidence    neurostimulation    automated    clinical    strategy    7b    slowness    points    society    falls    burden    aligned    neurodegenerative    delivers    independence    portable    living    medications    reducing    peripheral    inability    prevalence    stages    made    pd    spending    generator    body    self    families    safety    pattern    nih    dopamine    inputs    parkinson    treatment    feet    hesitation    treating    cord    walking    efficacy    priorities    substantial    central    more    causing    life    costly    gondolatm    mechanism    effectiveness    characterised    disabled    benefits    regulates    invasive    motions    motor    annual    brain    ninds    medical   

Project "GONDOLA" data sheet

The following table provides information about the project.

Coordinator
GONDOLA MEDICAL TECHNOLOGIES SA 

Organization address
address: CORSO ELVEZIA 9 A
city: LUGANO
postcode: 6900
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gondola-parkinson.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GONDOLA MEDICAL TECHNOLOGIES SA CH (LUGANO) coordinator 50˙000.00

Map

 Project objective

Parkinson’s disease (PD) is a neurodegenerative brain disorder, characterised by the inability of a person’s brain to produce a neurotransmitter called dopamine, lessening a person’s ability to regulate body motions. PD affects 10m people globally, its prevalence is expected to double by 2040. There is no cure for PD, current therapies focus on treating symptoms that undermine patients’ quality of life. Costs associated with PD are higher than its prevalence, causing substantial economic burden on individuals, families and society. In 2004, the annual spending in Europe on PD was €10.7b. As costly as they are, these therapies improve motor symptoms in the early stages of PD, but over time, patients have more and more reduced response to medications and become more disabled. Thus, they cannot be considered as ideal with regard to efficacy, long-term effectiveness and safety. NINDS (part of the US NIH) set recommendations addressing Gait as one of the 3 top priorities for advancing basic clinical research on PD. We have aligned ourselves with NINDS’ strategy through development of GondolaTM. GondolaTM is a portable medical device made for people living with PD. It delivers a non-invasive neurostimulation treatment named Automated Mechanical Peripheral Stimulation (AMPS). It is based on physical neurostimulations of specific points in both feet, which allow to increase the afferent inputs from the peripheral nervous system to the spinal cord, and induce a better functioning of the central pattern generator (the mechanism that regulates movements in the body). Four clinical studies have documented that AMPS is effective in improving motor skills in PD, particularly slowness of movements and freezing of gait. Users have derived the following benefits from the device: Reduced Freezing of gait, gait hesitation, slowness of movements, improved independence, self-confidence, fluidity in walking and balance, reducing the risk of falls and improving the quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GONDOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GONDOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More